Skip to main content

Haldol Decanoate Side Effects

Generic name: haloperidol

Medically reviewed by Drugs.com. Last updated on Jul 17, 2023.

Note: This document contains side effect information about haloperidol. Some dosage forms listed on this page may not apply to the brand name Haldol Decanoate.

Applies to haloperidol: oral solution, oral tablet. Other dosage forms:

Warning

Oral route (Tablet)

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Although the causes of death in clinical trials were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that antipsychotic drugs may increase mortality. It is unclear from these studies to what extent the mortality findings may be attributed to the antipsychotic drug as opposed to patient characteristics. Haloperidol is not approved for the treatment of patients with dementia-related psychosis.

Oral route (Solution)

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. Although the causes of death in clinical trials were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that antipsychotic drugs may increase mortality. It is unclear from these studies to what extent the mortality findings may be attributed to the antipsychotic drug as opposed to patient characteristics. Haloperidol injection is not approved for the treatment of patients with dementia-related psychosis.

Serious side effects of Haldol Decanoate

Along with its needed effects, haloperidol (the active ingredient contained in Haldol Decanoate) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking haloperidol:

More common

Less common

Rare

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking haloperidol:

Symptoms of overdose

Other side effects of Haldol Decanoate

Some side effects of haloperidol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to haloperidol: compounding powder, injectable solution, intramuscular solution, oral concentrate, oral tablet.

General

The most common side effects include extrapyramidal disorder, insomnia, and agitation.[Ref]

Nervous system

Acute dystonia usually occurred early in treatment.

Sedation may occur more frequently in elderly patients.

Akathisia usually occurred within 6 hours of administration and may be indistinguishable from psychotic agitation.[Ref]

Very common (10% or more): Extrapyramidal disorder (up to 34%), hyperkinesia (up to 13%), headache (up to 12%)

Common (1% to 10%): Tardive dyskinesia, dystonia, dyskinesia, akathisia, bradykinesia, hypertonia, somnolence, masked facies, tremor, dizziness, parkinsonism/parkinsonian effects

Uncommon (0.1% to 1%): Convulsion, akinesia, cogwheel rigidity, sedation, involuntary muscle contractions, gait disturbance, persistent tardive dyskinesia

Rare (0.01% to 0.1%): Motor dysfunction, neuroleptic malignant syndrome, nystagmus

Frequency not reported: Drowsiness, epileptic/grand mal seizure, vertigo, lethargy

Postmarketing reports: Opisthotonos[Ref]

Psychiatric

Very common (10% or more): Insomnia (up to 19%), agitation (up to 15%)

Common (1% to 10%): Depression, psychotic disorder

Uncommon (0.1% to 1%): Confusion, increased/decreased libido, restlessness, hallucinations

Frequency not reported: Apparent exacerbation of psychotic symptoms, anxiety, euphoria, agitation, apprehension, toxic psychosis, catatonic-like behavioral states[Ref]

Gastrointestinal

Common (1% to 10%): Constipation, dry mouth, salivary hypersecretion/hypersalivation, nausea, vomiting

Frequency not reported: Dyspepsia, diarrhea, heartburn, excessive salivation[Ref]

Genitourinary

Common (1% to 10%): Urinary retention, erectile dysfunction, sexual dysfunction

Uncommon (0.1% to 1%): Amenorrhea, dysmenorrhea, galactorrhea, breast discomfort/pain

Rare (0.01% to 0.1%): Menorrhagia, menstrual disorder

Frequency not reported: Priapism, oligomenorrhea, mastalgia, breast engorgement, lactation[Ref]

Cardiovascular

Common (1% to 10%): Orthostatic hypotension, hypotension

Uncommon (0.1% to 1%): Tachycardia, edema

Rare (0.01% to 0.1%): QT prolongation (on ECG)

Frequency not reported: Ventricular fibrillation, Torsade de pointes/polymorphous configuration of Torsade de pointes, ventricular tachycardia, extrasystoles, peripheral edema, venous thromboembolism, deep vein thrombosis, unusual bleeding, heat stroke

Postmarketing reports: Ventricular arrhythmia, cardiac arrest, hypertension[Ref]

QT prolongation, Torsade de pointes, ventricular arrhythmias/fibrillation/tachycardia and cardiac arrest occurred more frequently at high doses and/or in patients at risk for cardiovascular side effects.

Tachycardia and hypotension may occur more frequently in elderly patients. Hypotension occurred as a dose-related event.

Heat stroke included hot, dry skin, the inability to sweat, muscle weakness, and/or confusion.[Ref]

Metabolic

Common (1% to 10%): Weight increased/decreased

Frequency not reported: Hypoglycemia, hyperglycemia, loss of appetite, anorexia, hyponatremia

Postmarketing reports: Hyperammonemia[Ref]

Hyperammonemia occurred in a pediatric patient with citrullinemia (inherited disorder of ammonia excretion).[Ref]

Ocular

Common (1% to 10%): Oculogyric crisis, visual disturbance

Uncommon (0.1% to 1%): Blurred vision

Frequency not reported: Cataracts, retinopathy[Ref]

Dermatologic

Common (1% to 10%): Rash

Uncommon (0.1% to 1%): Photosensitivity reaction, urticaria, pruritus, hyperhidrosis

Frequency not reported: Exfoliative dermatitis, leukocytoclastic vasculitis, Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, maculopapular/acneiform skin reactions, alopecia[Ref]

Musculoskeletal

Common (1% to 10%): Muscle rigidity

Uncommon (0.1% to 1%): Torticollis, muscle spasms, musculoskeletal stiffness

Rare (0.01% to 0.1%): Trismus, muscle twitching

Postmarketing reports: Rhabdomyolysis[Ref]

Other

Common (1% to 10%): Hyperthermia

Uncommon (0.1% to 1%): Unusual tiredness/weakness

Frequency not reported: Neonatal drug withdrawal syndrome, sudden/unexpected death, face edema, hypothermia[Ref]

Hepatic

Common (1% to 10%): Abnormal liver function test

Uncommon (0.1% to 1%): Hepatitis, jaundice

Frequency not reported: Acute hepatic failure, cholestasis, impaired liver function[Ref]

Local

Common (1% to 10%): Injection site reaction

Frequency not reported: Injection site abscesses, localized erythema/swelling/tender lumps[Ref]

Respiratory

Uncommon (0.1% to 1%): Dyspnea

Rare (0.01% to 0.1%): Bronchospasm

Frequency not reported: Laryngeal edema, laryngospasm, pulmonary embolism, increased respiratory rate/depth, sore throat, bronchopneumonia/lethal bronchopneumonia[Ref]

Hematologic

Agranulocytosis included sore throat/fever and unusual bleeding/bruising, and typically occurred with concurrent use of other drugs.

Leukopenia and leukocytosis were usually mild and transient.[Ref]

Uncommon (0.1% to 1%): Leukopenia

Frequency not reported: Agranulocytosis, neutropenia, pancytopenia, thrombocytopenia, unusual bruising, decreased red blood cell counts, anemia, lymphocytosis, monocytosis, lymphomonocytosis[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Hypersensitivity reactions

Frequency not reported: Anaphylactic reaction[Ref]

Endocrine

Rare (0.01% to 0.1%): Hyperprolactinemia

Frequency not reported: Inappropriate antidiuretic hormone secretion, gynecomastia[Ref]

Inappropriate antidiuretic hormone secretion occurred with hyponatremia[Ref]

References

1. Product Information. Haldol (haloperidol). McNeil Pharmaceutical. 2002;PROD.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.